Please login to the form below

Not currently logged in
Email:
Password:

GSK to assist in manufacturing up to 60 million doses of Novavax’s COVID-19 vaccine in the UK

Vaccine candidate is expected to be submitted to UK regulatory authorities in Q2

GlaxoSmithKline (GSK) has signed an agreement to help make up to 60 million doses of Novavax’s COVID-19 vaccine NVX-CoV2373 in the UK.

The agreement between GSK, Novavax and the UK Vaccines Taskforce will see GSK provide fill and finish manufacturing capacity at its facility located in Barnard Castle, in the North East of England.

Although the parties need to negotiate a final agreement, technology transfer between GSK and Novavax is to begin immediately.

The UK government signed an advanced purchase agreement with Novavax in August 2020 for 60 million doses of NVX-CoV2373.

As part to the deal, Novavax conducted a phase 3 clinical trial of its vaccine candidate with support from the UK’s National Institute for Health Research (NIHR).

Novavax also partnered with FUJIFILM Diosynth Biotechnologies to manufacture certain components of the vaccine in the UK, including the protein antigen component.

In January, Novavax revealed the initial results from the UK trial of NVX-CoV2373 that showed the vaccine candidate had an overall efficacy rate of 89.3%, based on 62 PCR-confirmed, symptomatic COVID-19 cases.

Preliminary analysis also found that the UK variant was detected in over 50% of the PCR-confirmed cases, with 32 cases being caused by the UK variant, 24 by the non-variant and six ‘unknown’.

Based on this information, Novavax calculated that its vaccine is 95.6% effective against the original COVID-19 strain and 85.6% effective against the UK variant.

“GSK is delighted to support Novavax and the UK Vaccines Taskforce with this manufacturing arrangement for the UK and our Barnard Castle facility is now undertaking the rapid preparation work required to manufacture up to 60 million doses of this vaccine,” said Roger Connor, president of GSK Vaccines.

“We have ensured that we can deliver these volumes without impacting supply of our other vital medicines and vaccines, and without disruption to the other COVID-19 collaborations GSK is engaged in globally,” he added.

Novavax is expecting to submit its vaccine candidate for review by regulatory authorities in the UK during the second quarter of 2021.

Article by
Lucy Parsons

30th March 2021

From: Marketing

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Blue Latitude Health

Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...

Latest intelligence

InSite Events™ National Pharma Meeting: A Customer Story
How our client leveraged Impetus Digital’s white-glove service, 360° coverage and care, and award-winning InSite Events™ platform to successfully transfer their annual national meeting online....
Fear or encouragement, which is best to drive behaviour change?
The communications industry depends on fear of the perceived loss of something, in order to create the hope found in a product benefit. But, if if left too long unchecked,...
The unheard, unseen, and uncorrected effects of COVID-19
The disproportionate effects of the pandemic have been highlighted amongst ethnic minorities, so is it likely that ethnic minorities will be more worried about participating? And could this exacerbate inequalities...

Infographics